INVA Q4 2021 Earnings — Innoviva, Inc. Revenue & Financial Results | Market Cap Arena

INVAInnoviva, Inc.

$1B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$108M+19.0% YoY

Gross Profit

$108M100.0% margin

Operating Income

$105M97.1% margin

Net Income

$10M9.6% margin

EPS (Diluted)

$0.14

QoQ Revenue Growth

+10.0%

Cash Flow

Operating Cash Flow

$98M

Free Cash Flow

$76M

Stock-Based Comp.

$554,000

Balance Sheet

Total Assets

$926M

Total Liabilities

$400M

Stockholders' Equity

$415M

Cash & Equivalents

$202M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$108M	$90M	+19.0%
Gross Profit	$108M	$90M	+19.3%
Operating Income	$105M	$85M	+23.3%
Net Income	$10M	$54M	-80.8%

Revenue Segments

Royalty

$330M100%